Pharmaceutical cancer care for haematology patients on oral anticancer drugs : Findings from an economic, clinical and organisational analysis
© 2022 John Wiley & Sons Ltd..
OBJECTIVE: The clinical benefit of pharmaceutical cares in improving the quality-of-care outcomes is well demonstrated. Clinical pharmacy services are not systematically deployed in cancer units in the absence of economic data. The aim of this prospective, observational 1-year study was to evaluate the clinical, economic and organisational impacts of pharmaceutical care into a multidisciplinary day hospital for patients treated with oral cancer drugs.
METHODS: All pharmacists' interventions (PI) were documented and their impact and the probability of adverse drug events were assessed using the clinical, economic and organisational tool.
RESULTS: Among 360 admissions, an average of 1.81 PI per admission was accepted. Among 452 PI leading to a clinical benefit on the patient, 16.9% had a major impact, and 1.9% had an impact on survival. The large majority of PIs (87%) increased the quality-of-care organisation. The budget impact model showed a total cost savings and cost avoidance of €539,047 per year and a cost-benefit ratio of 7.07:1. The direct cost-benefit was €201,741, and the cost avoidance was €337,306.
CONCLUSION: Multidisciplinary care and pharmaceutical care are key elements to improve cancer patients' outcomes and avoid evitable healthcare costs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European journal of cancer care - 31(2022), 6 vom: 28. Nov., Seite e13753 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zerbit, Jeremie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 29.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ecc.13753 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347884202 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347884202 | ||
| 003 | DE-627 | ||
| 005 | 20231226034907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ecc.13753 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347884202 | ||
| 035 | |a (NLM)36273820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zerbit, Jeremie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical cancer care for haematology patients on oral anticancer drugs |b Findings from an economic, clinical and organisational analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 29.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: The clinical benefit of pharmaceutical cares in improving the quality-of-care outcomes is well demonstrated. Clinical pharmacy services are not systematically deployed in cancer units in the absence of economic data. The aim of this prospective, observational 1-year study was to evaluate the clinical, economic and organisational impacts of pharmaceutical care into a multidisciplinary day hospital for patients treated with oral cancer drugs | ||
| 520 | |a METHODS: All pharmacists' interventions (PI) were documented and their impact and the probability of adverse drug events were assessed using the clinical, economic and organisational tool | ||
| 520 | |a RESULTS: Among 360 admissions, an average of 1.81 PI per admission was accepted. Among 452 PI leading to a clinical benefit on the patient, 16.9% had a major impact, and 1.9% had an impact on survival. The large majority of PIs (87%) increased the quality-of-care organisation. The budget impact model showed a total cost savings and cost avoidance of €539,047 per year and a cost-benefit ratio of 7.07:1. The direct cost-benefit was €201,741, and the cost avoidance was €337,306 | ||
| 520 | |a CONCLUSION: Multidisciplinary care and pharmaceutical care are key elements to improve cancer patients' outcomes and avoid evitable healthcare costs | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a blood cancers | |
| 650 | 4 | |a economic | |
| 650 | 4 | |a leukaemia | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a myeloma | |
| 650 | 4 | |a pharmacist | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Kroemer, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Basile |e verfasserin |4 aut | |
| 700 | 1 | |a Detroit, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Decroocq, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Vignon, Marguerite |e verfasserin |4 aut | |
| 700 | 1 | |a Willems, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Deau-Fischer, Bénédicte |e verfasserin |4 aut | |
| 700 | 1 | |a Franchi, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Deschamps, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Contejean, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a Grignano, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Fouquet, Guillemette |e verfasserin |4 aut | |
| 700 | 1 | |a Birsen, Rudy |e verfasserin |4 aut | |
| 700 | 1 | |a Mondesir, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rocquet, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Huon, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Marty-Reboul, Jeanne |e verfasserin |4 aut | |
| 700 | 1 | |a Bouscary, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer care |d 1993 |g 31(2022), 6 vom: 28. Nov., Seite e13753 |w (DE-627)NLM075117835 |x 1365-2354 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2022 |g number:6 |g day:28 |g month:11 |g pages:e13753 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ecc.13753 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2022 |e 6 |b 28 |c 11 |h e13753 | ||